EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Ducournau, P. [1 ]
Latimer, N. [2 ]
Sabate, E. [1 ]
Walzer, S. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[2] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66575-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A471 / A472
页数：2
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [2] A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial
    Hoff, P.
    Clarke, S.
    Cunningham, D.
    Van Cutsem, E.
    Moore, M.
    Schmoll, H. J.
    Tabernero, J.
    Mueller, B.
    De Gramont, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 324 - 324
  • [3] Adjuvant Modified FOLFOX-4 in Patients with Stage III Rectum Adenocarcinoma
    Cihan, Sener
    Uncn, Dogan
    Babacan, Nalan Akgul
    Ozdemir, Nuriye
    Odabas, Hatice
    Aksoy, Sercan
    Oksuzoglu, Berna
    Zengin, Nurullah
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (04) : 967 - 970
  • [4] Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of stage III colon cancer in the UK
    Aballea, S.
    Chancellor, J. V. M.
    Raikou, M.
    Drummond, M. F.
    Jourdan, S.
    Carita, P.
    Bridgewater, J.
    Boler, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 178 - 178
  • [5] COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE plus OXALIPLATIN) VERSUS FOLFOX-4 (5-FU/LV + OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Prolla, G.
    Borges, L. G.
    Santos, E.
    VALUE IN HEALTH, 2010, 13 (07) : A268 - A269
  • [6] Cost-Effectiveness of Adjuvant FOLFOX Therapy for Stage III Colon Cancer in Japan Based on the MOSAIC Trial
    Shiroiwa, Takeru
    Takeuchi, Toshihiro
    Fukuda, Takashi
    Shimozuma, Kojiro
    Ohashi, Yasuo
    VALUE IN HEALTH, 2012, 15 (02) : 255 - 260
  • [7] Costs of Adjuvant Chemotherapy With Oxaliplatin in Stage III Colon Cancer - Comparing the Three Schemes Standards: FOLFOX-4, FLOX and XELOX
    Ruiz, G. Calderillo
    Melchor, J.
    Ruiz, E.
    Herrera, A.
    Meneses, A.
    Albarran, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S259 - S259
  • [8] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    S Eggington
    P Tappenden
    A Pandor
    S Paisley
    M Saunders
    M Seymour
    P Sutcliffe
    J Chilcott
    British Journal of Cancer, 2006, 95 : 1195 - 1201
  • [9] COSTS OF ADJUVANT CHEMOTHERAPY WITH OXALIPLATIN IN STAGE III COLON CANCER: COMPARING THE THREE SCHEMES STANDARDS: FOLFOX-4, FLOX AND XELOX
    Calderillo, G.
    Melchor, J.
    Ruiz, E.
    Meneses, A.
    Albarran, A.
    VALUE IN HEALTH, 2011, 14 (07) : A451 - A451
  • [10] Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
    Eggington, S.
    Tappenden, P.
    Pandor, A.
    Paisley, S.
    Saunders, M.
    Seymour, M.
    Sutcliffe, P.
    Chilcott, J.
    BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1195 - 1201
12345